Clinical Trial Update: TGRX-326 Pharmacokinetic Drug Interaction [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic drug interaction study of TGRX-326 in Non-Small Cell Lung Cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TGRX-326

Snippet

Sponsor: Shenzhen TargetRx Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED